United States signs about $1 bln order for GSK-Vir COVID-19 antibody drug

The United States has signed contracts worth roughly $1 billion to secure antibody-based COVID-19 treatment sotrovimab from GSK and Vir Biotechnology , the drugmakers said on Wednesday, with supply expected by mid-December.

 

Also Read: International travellers head to the United States as flights reopen

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)